MLchartDataset catalogue

Suberoylanilide hydroxamic acid

Term · Oncology and biomedicine · MLC-T-ONC-008361

A drug used to treat cutaneous T-cell lymphoma that came back, got worse, or did not get better during or after treatment with two systemic therapies. It is also being studied in the treatment of other types of cancer. Suberoylanilide hydroxamic acid blocks certain enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase inhibitor. Also called SAHA, vorinostat, and Zolinza.

Table 1. Record
IdentifierMLC-T-ONC-008361
FieldOncology and biomedicine
SynonymsSAHA; vorinostat; Zolinza
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-008361",
  "term": "Suberoylanilide hydroxamic acid",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat cutaneous T-cell lymphoma that came back, got worse, or did not get better during or after treatment with two systemic therapies. It is also being studied in the treatment of other types of cancer. Suberoylanilide hydroxamic acid blocks certain enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase inhibitor. Also called SAHA, vorinostat, and Zolinza.",
  "synonyms": [
    "SAHA",
    "vorinostat",
    "Zolinza"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/suberoylanilide-hydroxamic-acid/"
}

Record 15,743 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.